| Schedule of Basic and Diluted Net Loss Per Share |
The following table sets forth the
computation of the Company’s basic and diluted net loss per share for:
| |
|
Three-months ended September 30, 2020 |
|
| |
|
(Unaudited) |
|
| |
|
Net Loss (Numerator) |
|
|
Shares (Denominator) |
|
|
Per share
amount |
|
| Basic loss per share |
|
$ |
(1,354,331 |
) |
|
|
755,847 |
|
|
$ |
(1.79 |
) |
| Effect of dilutive securities—Common stock options, warrants, and convertible notes |
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Diluted loss per share |
|
$ |
(1,354,331 |
) |
|
|
755,847 |
|
|
$ |
(1.79 |
) |
| |
|
Three-months ended September 30, 2019 |
|
| |
|
(Unaudited) |
|
| |
|
Net Loss (Numerator) |
|
|
Shares (Denominator) |
|
|
Per share
amount |
|
| Basic loss per share |
|
$ |
(1,433,626 |
) |
|
|
683,731 |
|
|
$ |
(2.10 |
) |
| Effect of dilutive securities—Common stock options, warrants, and convertible notes |
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Diluted loss per share |
|
$ |
(1,433,626 |
) |
|
|
683,731 |
|
|
$ |
(2.10 |
) |
| |
|
Nine-months ended September 30, 2020 |
|
| |
|
(Unaudited) |
|
| |
|
Net Loss (Numerator) |
|
|
Shares (Denominator) |
|
|
Per share
amount |
|
| Basic loss per share |
|
$ |
(4,057,541 |
) |
|
|
736,719 |
|
|
$ |
(5.51 |
) |
| Effect of dilutive securities—Common stock options, warrants, and convertible notes |
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Diluted loss per share |
|
$ |
(4,057,541 |
) |
|
|
736,719 |
|
|
$ |
(5.51 |
) |
| |
|
Nine-months ended September 30, 2019 |
|
| |
|
(Unaudited) |
|
| |
|
Net Loss (Numerator) |
|
|
Shares (Denominator) |
|
|
Per share
amount |
|
| Basic loss per share |
|
$ |
(3,650,740 |
) |
|
|
678,108 |
|
|
$ |
(5.38 |
) |
| Effect of dilutive securities—Common stock options, warrants, and convertible notes |
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Diluted loss per share |
|
$ |
(3,650,740 |
) |
|
|
678,108 |
|
|
$ |
(5.38 |
) |
|
| Schedule of Shares of Common Stock Equivalents Were Excluded from Computation of Diluted Net Loss Per Share |
The following outstanding shares
of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because
including them would have been antidilutive for the periods ended:
| |
|
September 30, 2020 |
|
|
September 30, 2019 |
|
| |
|
|
(Unaudited) |
|
|
|
(Unaudited) |
|
| Common stock underlying convertible notes |
|
|
549,527 |
|
|
|
47,012 |
|
| Common stock underlying options |
|
|
171,969 |
|
|
|
202,246 |
|
| Common stock underlying warrants |
|
|
631,878 |
|
|
|
513,875 |
|
| Total common stock equivalents |
|
|
1,353,374 |
|
|
|
763,133 |
|
|